Tan Shanjun, Yu Wenkui, Lin Zhiliang, Chen Qiyi, Shi Jialiang, Dong Yi, Duan Kaipeng, Bai Xiaowu, Xu Lin, Yu Zhen, Li Jieshou, Li Ning
Research Institute of General Surgery, Jinling Hospital, Medical School of Nanjing University.
Biol Pharm Bull. 2015;38(1):122-6. doi: 10.1248/bpb.b14-00643. Epub 2014 Oct 22.
Berberine, an isoquinoline alkaloid derived from many medicinal plants, has been extensively used to treat various gastrointestinal diseases. In the present study, we investigated whether berberine could ameliorate intestinal mucosal barrier damage induced by peritoneal air exposure for 3 h. Peritoneal air-exposure rats received 100, 150, and 200 mg/kg berberine orally via gavage four times before and after surgery. Blood and terminal ileum samples were collected 24 h after surgery. The serum D-lactate levels were determined using an enzyme-linked immunosorbent assay (ELISA) kit. Intestinal permeability was determined by measuring the intestinal clearance of fluorescein isothiocyanate (FITC)-dextran (FD4). Intestinal inflammation was assessed by measuring myeloperoxidase activity. Intestinal histopathology was also assessed. The results revealed that berberine decreased the serum D-lactate level, intestinal FD4 clearance, and myeloperoxidase activity. Edema and inflammation were reduced by berberine in the intestinal mucosa and submucosa, and the Chiu's scores, indices of intestinal mucosal injury, also decreased in the berberine-treated group. In addition, berberine exerted these protective effects in a dose-dependent manner, with a significant difference from the control group at doses of 150 and 200 mg/kg. The results suggest that berberine could ameliorate intestinal mucosal barrier damage induced by peritoneal air exposure, which is linked to its anti-inflammatory activity. Berberine may be a promising treatment for intestinal mucosal barrier damage in open abdominal surgery.
黄连素是一种从多种药用植物中提取的异喹啉生物碱，已被广泛用于治疗各种胃肠道疾病。在本研究中，我们调查了黄连素是否能改善因腹膜暴露于空气3小时所诱导的肠黏膜屏障损伤。在手术前后，腹膜暴露于空气的大鼠通过灌胃方式口服给予100、150和200mg/kg的黄连素，每日4次。术后24小时采集血液和回肠末端样本。使用酶联免疫吸附测定（ELISA）试剂盒测定血清D-乳酸水平。通过测量异硫氰酸荧光素（FITC）-葡聚糖（FD4）的肠道清除率来测定肠道通透性。通过测量髓过氧化物酶活性评估肠道炎症。还评估了肠道组织病理学。结果显示，黄连素降低了血清D-乳酸水平、肠道FD4清除率和髓过氧化物酶活性。黄连素减轻了肠黏膜和黏膜下层的水肿和炎症，在黄连素治疗组中，肠黏膜损伤指数Chiu评分也降低。此外，黄连素以剂量依赖的方式发挥这些保护作用，在150和200mg/kg剂量时与对照组有显著差异。结果表明，黄连素可改善腹膜暴露于空气所诱导的肠黏膜屏障损伤，这与其抗炎活性有关。黄连素可能是治疗开放性腹部手术中肠黏膜屏障损伤的一种有前景的药物。
